Finding. Blocking Clever-1 with bexmarilimab starves AML mitochondria of lipoprotein-derived lipid, breaks complex IV assembly and cristae, and erases spare respiratory capacity. The receptor itself is visible on mitochondria and co-purifies with mitochondrial proteins including ATAD3. OXPHOS-high leukemia models are the most sensitive, especially when lipid is scarce.
Why this paper matters
Therapy-resistant AML is a mitochondrial fitness problem as much as a genotyping problem. Cells that keep oxidizing fat and holding reserve respiratory capacity outlast chemotherapy. Clever-1 (STAB1) entered oncology as a macrophage scavenger and immune modulator. Ylitalo, Mickos, Hakoniemi and colleagues argue for a leukemia-cell-intrinsic job: keeping mitochondria lipid-fed and structurally competent.
That claim, if it holds, reconnects a clinical antibody to organelle biochemistry. Bexmarilimab is not being asked here to re-educate macrophages. It is being asked to collapse leukemic OXPHOS.
The mechanistic chain
The abstract lays out an ordered sequence. First, mitochondrial transcriptional reprogramming. Then OXPHOS suppression. Localization is not inferred from a GFP fusion alone: immunoelectron microscopy puts Clever-1 at mitochondria, and proteomics remint its partnership list toward mitochondrial-linked proteins, ATAD3 among them. Functionally, lipoprotein-derived lipid stops reaching mitochondria; mitochondrial lipid composition shifts; complex IV assembly falters; cristae architecture fails; dysfunctional mitochondria accumulate; spare capacity falls.
This is a better story than “OCR went down.” Spare capacity and complex IV assembly are the right layer for a lipid-trafficking receptor. ATAD3 sits at nucleoid–inner-membrane contacts and is already a mitochondrial-DNA and cristae suspect — a plausible, still unproven, effector.
Constraints
The abstract is silent on which AML genotypes, which in vivo models, and how much of the phenotype is tumor-cell autonomous versus stromal. Clever-1’s immune functions are real; they can confound animal survival even if the cell-line mitochondrial phenotype is clean. Lipid restriction as a stress test is scientifically fair and clinically awkward — patients are not cultured in delipidated media.
How to use it
If you track AML metabolic vulnerabilities, add Clever-1 to the same shelf as OXPHOS inhibitors and fatty-acid oxidation blockers, with a different entry point: receptor-mediated lipid delivery and complex IV. If you track mitochondrial lipid trafficking, this is a rare antibody handle. Stratify on high baseline OXPHOS and lipid dependence. Demand ATAD3 epistasis and in vivo leukemia-initiating assays before calling it a therapeutic map.